missing translation for 'onlineSavingsMsg'
Learn More

Invitrogen™ TCR V alpha 24 J alpha 18 Monoclonal Antibody (6B11), eBioscience™, Invitrogen™

Mouse Monoclonal Antibody

£1376.00 - £3115.00

Specifications

Antigen TCR V alpha 24 J alpha 18
Clone 6B11
Concentration 0.5 mg/mL
Applications Flow Cytometry
Classification Monoclonal
View More Specs

Products 2
Product Code Brand Quantity Price Quantity & Availability  
Product Code Brand Quantity Price Quantity & Availability  
17138495
View Documents
Invitrogen™
14-5806-37
2 mg
£1376.00
2mg
View alternative products
Save Up to 
»
Please to purchase this item. Need a web account? Register with us today!
17148495
View Documents
Affymetrix eBioscience
14-5806-95
10 mg This item is currently unavailable or has been discontinued.
View the product page for possible alternatives.
N/A View alternative products
Save Up to 
»
Description

Description

The 6B11 MAb reacts with an epitope of the CDR3 formed by the germ-line configuration of the V alpha 24 and J alpha 18 of the TCR alpha locus, which results in the expression of an invariant T-cell receptor (TCR) expressed by invariant NK T cells (iNKT). This TCR is homologous to the murine V alpha 14J alpha 18. This TCR alpha chain pairs with a restricted set of rearranged TCR beta chains, with V beta 11 being the most prominent in humans. NK T cells are restricted by the CD1d molecule and are activated by a CD1d-presented glycolipid ligand, which results in the rapid production of IL-4, IL-13 and IFN gamma. Although iNKT cells have NK-like cytolytic activity, they are considered regulators of immune responses because they rapidly produce large amounts of both Th1 and Th2 cytokines in autoimmune disease, infectious disease, and cancer. The number of iNKT cells present in peripheral blood of normal humans shows considerable variability ranging from 0.01-1% of total peripheral T cells.

The ability of T cell receptors (TCR) to discriminate foreign from self-peptides presented by major histocompatibility complex (MHC) class II molecules is essential for an effective adaptive immune response. TCR recognition of self-peptides has been linked to autoimmune disease. Mutant self-peptides have been associated with tumors. Engagement of TCRs by a family of bacterial toxins know as superantigens has been responsible for toxic shock syndrome. Autoantibodies to V beta segments of T cell receptors have been isolated from patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The autoantibodies block TH1-mediated inflammatory autodestructive reactions and are believed to be a method by which the immune system compensates for disease. Most human T cells express the TCR alpha-beta and either CD4 or CD8 molecule (single positive, SP). A small number of T cells lack both CD4 and CD8 (double negative, DN). Increased percentages of alpha-beta DN T cells have been identified in some autoimmune and immunodeficiency disorders. Gamma-delta T cells are primarily found within the epithelium. They show less TCR diversity and recognize antigens differently than alpha-beta T cells. Subsets of gamma-delta T cells have shown antitumor and immunoregulatory activity.
Specifications

Specifications

TCR V alpha 24 J alpha 18
0.5 mg/mL
Monoclonal
Liquid
RUO
PBS with 0.09% sodium azide; pH 7.2
IgG1 κ
Affinity chromatography
Antibody
6B11
Flow Cytometry
Unconjugated
Mouse
Human
Va24; Valpha24
Primary
4°C
Videos
SDS
Documents

Documents

Product Certifications
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.